MMN usually presents with pure motor symptoms only, and that while it is unlikely to be misdiagnosed as EN by an experienced neurologist or neuromuscular specialist, it occasionally presents with vague, unrelated sensory symptoms. General physicians and even certain neurologists may have seen very few cases and may mistake some MMN presentations, especially early on and when focal in distribution, for EN. MMN commonly affects dexterity and walking ability but most patients maintain autonomy 9 and a high percentage remain employed. 10 However, if untreated, its clinical course tends to be chronic and protracted, and significant functional impairment may result. [11] [12] [13] If MMN is misdiagnosed as EN, the subsequent delay in making the correct diagnosis may result in progression in the condition and significant motor disability. 14 This article aims to discuss the comparative signs and the diagnoses of MMN and EN and identify the issues in diagnosing the conditions correctly.
Diagnosis of Entrapment Neuropathy and Multifocal Motor Neuropathy
MMN is a demyelinating neuropathy, characterized by CB of myelinated motor nerves that can lead to axonal loss as the disease progresses, resulting in increasing weakness and muscle atrophy. nerves that is out of proportion to muscle atrophy. Weakness usually starts in a distribution of a single peripheral nerve with unilateral wrist drop, foot drop, or grip weakness. [1] [2] [3] 15 It can differentially involve branches of a peripheral nerve; a common clinical finding noted in some patients is the presence of differential weakness of finger extensors. 16 The European Federation of Neurological Societies (EFNS) has defined the diagnostic criteria for MMN (see Table 1 ). 15, 17 The condition usually presents with slowly progressive focal weakness and atrophy without pain or sensory complaints (see Figure 2 ). There is often focal or multifocal involvement of the upper-extremity motor nerves in the forearm or upper arm. specificity. 21 Electrodiagnostic study assists significantly in validating the diagnosis, determining the pathology and prognosis, as well as ruling out other mimickers. Tables 1 and 2) . 17 Unlike EN, in MMN, CB is noted at nonentrapment sites (see Figure 3 ). This is an important electrodiagnostic finding, which, in the clinical context, can hint to the diagnosis of MMN.
Using electrodiagnostic criteria, as recommended by the EFNS guidelines, can help in identifying MMN from EN (see Table 2 ). 17 According to these criteria, the grading of CB is defined as definite (including negative-peak CMAP area reduction on proximal versus distal stimulation of at least 50% whatever the nerve segment length [median, ulnar, and peroneal])
or probable (including negative-peak CMAP area reduction of at least 30% over a long segment [e.g., wrist to elbow or elbow to axilla] of an upper-limb nerve with increase of proximal to distal negative-peak CMAP duration to ≤30%). Also, normal sensory-nerve conduction studies are required in upper-limb segments with CB (please see Table 2 for electrodiagnostic details). Electrodiagnostic testing is a useful tool in the hand of an experienced neuromuscular specialist. However, on rare occasions, and especially when electrodiagnostic testing is not properly performed, electrodiagnostic testing can result in the misdiagnosis of MMN as EN.
14 Supporting criteria to the diagnosis of MMN include imaging of the nerves, particularly the brachial plexus, showing abnormal enhancement. 17 These studies, including neuromuscular ultrasound, are being increasingly used as adjunct tools in the diagnosis of EN. In CTS, imaging of the median nerve's cross-sectional area at the wrist provides additional information and shows pathologic nerve swelling and other anomalies that compress the median nerve. 28 In MMN, high-resolution ultrasonography is now 
Definite motor CB*
Negative-peak CMAP area reduction on proximal versus distal stimulation of at least 50% whatever the nerve segment length (median, ulnar, and peroneal)
Negative-peak CMAP's amplitude on stimulation of the distal part of the segment with motor CB must be >20% of the lower limit of normal and >1 mV and increase of proximal to distal negative-peak CMAP duration must be ≤30%
Probable motor CB*
Negative-peak CMAP area reduction of at least 30% over a long segment (e.g., wrist to elbow or elbow to axilla) of an upper limb nerve with increase of proximal to distal negative-peak CMAP duration ≤30%; OR Negative-peak CMAP area reduction of at least 50% (same as definite) with an increase of proximal to distal negative-peak CMAP duration >30%.
Normal sensory nerve conduction in upper limb segments with CB

*Evidence for conduction block (CB) must be found at sites distinct from common entrapment or compression syndromes. CMAP = compound muscle action potential.
US NEUROLOGY available and can show different patterns of nerve enlargement between inflammatory neuropathies and axonal and inherited polyneuropathies, as well as show increased hypo-echogenicity and increased intraneural vascularization. 29, 30 Magnetic resonance neurography (MRN) may also help in diagnosis; it shows focal enlargement and increased signal intensity of the brachial plexus on T2-weighted images.
31
Current Guidelines and Treatment Paradigms
In the case of MMN, current consensus guidelines recommend intravenous immunoglobulin (IVIG) as the standard, evidence-based therapy for MMN. 15, 32 In a study of 88 patients with MMN, 95% responded to IVIG therapy: nonresponders had longer disease duration before the first treatment, highlighting the importance of early treatment. 4 The recommended treatment options of American Academy of Orthopaedic Surgeons (AAOS)
for EN include surgery, wrist splinting, steroid injections, and oral steroids. 33 Surgery is associated with better long-term outcomes than splinting. 34 However, these treatments for EN either would be unnecessary and would fail or may worsen the symptoms in MMN (see Figure 2) , 35 highlighting the importance of correct diagnosis.
Cases of Multifocal Motor Neuropathy Misdiagnosed as Entrapment Neuropathy Case 1
The patient is a 58-year-old male who noted painless weakness in his left 
Summary and Concluding Remarks
MMN is a rare, treatable neuropathy, but good long-term outcomes are dependent on early treatment. It is therefore important to diagnose MMN and differentiate it from other conditions. It differs from typical EN in that it predominantly affects motor nerve fibers and has a strikingly restricted distribution, with characteristic topographical distribution, affecting upper more than lower extremity, and with predilection to the distal segments.
Misdiagnosis should rarely occur since the nerve involvement in either of these disorders is rarely at sites of common nerve entrapment;
however, despite the existence of good diagnostic criteria, when MMN is confined to a small group of nerves, there is significant overlap with EN. Furthermore, misdiagnosis may have serious consequences in terms of treatment. The ability to recognize MMN and the ability to distinguish it from other diseases of peripheral nerve, such as EN, are important clinical skills. The cases presented have illustrated some of the issues and complications that can ensue as a result of delayed diagnosis or wrong therapy, such as surgical intervention for a presumed diagnosis of EN.
Oral corticosteroid treatment, occasionally used as nonsurgical treatment in early EN conditions, could also potentially worsen symptoms in MMN.
Clinical trials investigating alternative techniques for the diagnosis of MMN are ongoing. 36 However, there remains a need for future studies to further understand the pathogenesis of MMN in order to develop more alternative and efficacious treatment options. ■
